Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + imatinib
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of docetaxel, a taxane chemotherapy agent, and imatinib mesylate, a tyrosine kinase inhibitor. This combination has been studied for its potential synergistic effects in various cancer types, particularly in recurrent or resistant solid tumors. Imatinib appears to enhance docetaxel's effectiveness by blocking antiapoptotic signaling pathways induced by docetaxel treatment and potentially improving drug delivery to tumors.
- Other names
- docetaxel and imatinib mesylateimatinib mesylate and docetaxel
02
Targets
ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)BCR (Immunoglobulin G B Cell Receptor)TUBB (Tubulin (alpha and beta subunits))NF-κBPDGFRA (Platelet-derived growth factor receptor alpha)PDGFRB (Platelet-derived growth factor receptor beta)
Beyond the preview
Go deeper on docetaxel + imatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + imatinib.